Physician Support

Reimbursement Support

Reimbursement Codes and Allowables

Reimbursement Guide

Patient Education

Physician Information


	Bayer Global
	Bayer Corporate - USA

	general conditions of use privacy statement imprint © 2007 Bayer HealthCare Pharmaceuticals

To assist physicians in patient management, the patient education link includes information on prostate diseases as well as prostate cancer, helpful links, patient FAQs, and a patient-friendly package insert. Under the physician information link, you'll find physician FAQs and details on clinical trials.


		Reimbursement Support
		Reimbursement Codes and Allowables
		Reimbursement Guide
		Patient Education
		Physician Information

Viadur (leuprolide acetate implant) is a once-yearly implant for the palliative treatment of advanced prostate cancer. Available in the United States, Viadur offers patients 12-month, continuous androgen reduction – an alternative to the leuprolide injections currently on the market.

Side Effects Shown in Clinical Trials

In clinical trials the most common systemic side effects reported with Viadur were vasodilation (hot flashes, 67.9 %), asthenia (loss of strength, 7.6 %), gynecomastia (6.9 %), depression (5.3 %), and sweating (5.3 %). The most common local side effects were bruising (34.6 %) and burning (5.6 %).

Viadur is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction and spinal cord compression.


	Prescribing and Safety Information


	Important Safety Considerations Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression. The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).
	Distributed and Marketed by:	Manufactured by:
	Bayer HealthCare Pharmaceuticals 6 West Belt, Wayne, NJ 07470 USA
	© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation. The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.